Navigation Links
The unsolved mystery of kava toxicity
Date:7/13/2011

A major new review of scientific knowledge on kava a plant used to make dietary supplements and a trendy drink with calming effects has left unsolved the mystery of why Pacific Island people can consume it safely, while people in the United States, Europe, and other Western cultures sometimes experience toxic effects. The article appears in ACS' journal Chemical Research in Toxicology.

Line Olsen and colleagues point out that for centuries, people of the Pacific Islands have safely consumed a beverage made from crushed kava roots. Kava'scalming effects made it popular in Western cultures in the 1990s, when people also began to use a herbal supplement for the treatment of anxiety, emotional stress and sleep problems. But in 2001, reports of liver damage among Westerners who took kava supplements gained widespread attention. Many Western countries, including the United States, the United Kingdom, and Canada, ban or regulate the sale of kava products. To determine why kava is toxic to some people but not to others, the researchers sifted through the scientific studies published on the topic.

Their review of 85 scientific studies on kava toxicity found no consensus on kava toxicity, despite several theories that have emerged over the years. Culprits include methods for preparing kava, the particular species of kava used, the possible toxicity of substances produced by the body when kava is digested and genetic differences among consumers. "To date, there remains no indisputable reason for the increased prevalence of kava-induced hepatotoxicity in Western countries," the researchers say.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Scripps Research scientists solve mystery of nerve disease genes
2. River mystery solved
3. Team solves decades-old molecular mystery linked to blood clotting
4. New genetic study helps to solve Darwins mystery about the ancient evolution of flowering plants
5. Bacterial genome may hold answers to mercury mystery
6. 44-year-old mystery of how fleas jump resolved
7. Stretching the truth: JILA biophysicists help unravel DNA stretching mystery
8. Rice physicists help unravel mystery of repetitive DNA segments
9. Mystery dissolves with calcium pump discovery
10. VIMS scientists help solve mystery of alien pod
11. A mystery solved: How genes are selectively silenced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... June 15 Robert H. Wurtz, PhD, a pioneer and ... the 2010 Neuroscience Prize of The Peter and Patricia Gruber ... and controls eye movements laid the groundwork for subsequent research ... scientists to a deeper understanding of how the brain is ...
... new study shows that humans and tiny aquatic animals known ... to sex. Barely visible without a microscope, rotifers eat ... But the females of certain rotifer species can do something ... themselves, or they can initiate a process that allows sexual ...
... part of the 20th century have prevented massive amounts ... equivalent of 590 billion metric tons of carbon dioxide ... Stanford Earth scientists. The yield improvements reduced the ... typically involves burning of trees and other plants, which ...
Cached Biology News:Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 2Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 3New study documents use of hormone progesterone in simple microscopic aquatic animals 2New study documents use of hormone progesterone in simple microscopic aquatic animals 3New study documents use of hormone progesterone in simple microscopic aquatic animals 4High-yield agriculture slows pace of global warming, say Stanford researchers 2High-yield agriculture slows pace of global warming, say Stanford researchers 3High-yield agriculture slows pace of global warming, say Stanford researchers 4
(Date:5/27/2015)... May 27, 2015 Expanding in a ... manufacturer Avalon Biomed Inc. recently inked a ... Mokuda Dental Co. Ltd. , the largest endodontic distributor ... the international market for Avalon Biomed, which manufactures Grey ... tricalcium silicate-based dental cements that have won renown from ...
(Date:5/27/2015)... SAN FRANCISCO, Calif. , May 27, 2015 ... for the treatment of cancer, today announced the ... financial officer and Cynthia Ladd as ... joining CytomX, Goeltz was chief financial officer of ... served as an independent consultant and legal counsel ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... an update on the status of the Company,s ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 3,085 and 21 shares of Series A Preferred ...
(Date:5/26/2015)... WORMS, GERMANY (PRWEB) May 26, 2015 ... W. R. Grace & Co. (NYSE: GRA) announces ... received good manufacturing practice (GMP) certification from EXCiPACTâ„¢, ... distributors of pharmaceutical excipients. , All ... brand of pharmaceutical grade excipient silica gels have ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... revolutionary surgical instrument system that is smaller in diameter than a ... implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will ... Arizona starting on March 12, 2009. , ... Winston-Salem, ...
... In ClearTrial v2.7, the newest version of ... Portfolio Planning capability which enables clinical development ... into portfolio-level forecasts in minutes. The ... monthly resource demand, and timelines across a ...
... Enobia Pharma, an emerging Canadian biotech company ... disorders, today announced completion of target enrollment in ... a severe form of hypophosphatasia. Enobia is ... the treatment of this rare and often crippling ...
Cached Biology Technology:VGI Announces the Launch of DISMISS Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: